<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12845">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02939703</url>
  </required_header>
  <id_info>
    <org_study_id>TRIMD FH 942699</org_study_id>
    <nct_id>NCT02939703</nct_id>
  </id_info>
  <brief_title>Integrating Quantitative Energetics Determines the Microbiome's Contribution to Energy Balance</brief_title>
  <official_title>Integrating Quantitative Energetics Determines the Microbiome's Contribution to Energy Balance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translational Research Institute for Metabolism and Diabetes, Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Arizona State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pennington Biomedical Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Translational Research Institute for Metabolism and Diabetes, Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect data to examine how diet impacts the composition and
      function of the bacteria in your large intestine.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure energy balance</measure>
    <time_frame>90 days</time_frame>
    <description>Measure energy balance through whole room calorimetry, controlled diet, and fecal collection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure changes in the gut microbiota</measure>
    <time_frame>90 days</time_frame>
    <description>Measure changes in enteroendocrine hormone secretion, hunger/satiety, and food intake</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Western diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be randomly assigned to either a Western diet or a Microbiome Enhancer diet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Microbiome Enhancer diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be randomly assigned to either a Western diet or a Microbiome Enhancer diet.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dual-energy X-ray absorptiometry (DEXA)/ Magnetic resonance spectroscopy (MRS)</intervention_name>
    <description>A DEXA scan for measurement of body fat and muscle content will be completed. The MRS will assess body fat distribution, liver fat, and organ size analysis.</description>
    <arm_group_label>Western diet</arm_group_label>
    <arm_group_label>Microbiome Enhancer diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>23-hour Metabolic Calorimetry</intervention_name>
    <description>The 23 hour Metabolic Calorimetry stay is in a specialized room that measures the amount of oxygen the subject uses and the amount of carbon dioxide they produce. Urine and fecal collection will take place during time spent in the Metabolic Chambers.</description>
    <arm_group_label>Western diet</arm_group_label>
    <arm_group_label>Microbiome Enhancer diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Whole Room Calorimetry</intervention_name>
    <description>Continuous 23 hours a day in a specialized room that measures the amount of oxygen used, and the amount of carbon dioxide produced. A radiotransmitter pill (small silicone coated capsule) will be taken upon entering the whole room calorimeter. The pill will record core temperature, pressure, and PH level for the duration of the stay in the whole room calorimeter.</description>
    <arm_group_label>Western diet</arm_group_label>
    <arm_group_label>Microbiome Enhancer diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Polyethylene glycol (PEG)</intervention_name>
    <description>to measure fecal energy and calculate diet energy extraction and digestion.</description>
    <arm_group_label>Western diet</arm_group_label>
    <arm_group_label>Microbiome Enhancer diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Able to communicate meaningfully with the investigator and legally competent to
             provide informed written consent

          2. Age 18 - 45 years, inclusive

          3. Weight stable (+/- 3 kg) during the 6 months prior to enrollment

          4. BMI â‰¤ 30 kg/m2

        Exclusion Criteria:

          1. History or presence of cardiovascular disease (unstable angina, myocardial infarction
             or coronary revascularization within 6 months, clinically significant abnormalities
             on EKG, presence of cardiac pacemaker, implanted cardiac defibrillator)

          2. History of type 1 or type 2 diabetes

          3. Bleeding disorders

          4. Acute or chronic infections

          5. Hepatitis and/or cirrhosis

          6. Severe asthma or chronic obstructive pulmonary disease

          7. Renal insufficiency or nephritis

          8. Thyroid dysfunction (suppressed TSH, elevated TSH if symptomatic, elevated thyroid
             stimulating hormone (TSH) if asymptomatic)

          9. Uncontrolled hypertension (BP &gt;160 mmHg systolic or &gt;100 mmHg diastolic)

         10. Prior bariatric surgery

         11. Inflammatory bowel disease or malabsorption

         12. Cancer within the last 3 years (except non-melanoma skin cancer or treated cervical
             carcinoma in situ)

         13. History of major depression

         14. History of eating disorders

         15. Cushing's disease or syndrome

         16. Untreated or inadequately controlled hypo- or hyperthyroidism

         17. Active rheumatoid arthritis or other inflammatory rheumatic disorder

         18. Pregnant or nursing females or females less than 6 months postpartum from the
             scheduled date of collection.

         19. Tobacco use within the past 3 months

         20. Metal implants (pace-maker, aneurysm clips) based on Investigator's judgment at
             Screening.

         21. Unable to participate in MRI or MRS assessments due to physical limitations of
             equipment tolerances (e.g. MRI bore size) based on Investigator's judgment at
             Screening.

         22. Unable to tolerate MRI/MRS imaging or claustrophobia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven R Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patty Ford</last_name>
    <phone>407-303-7100</phone>
    <email>trimd@flhosp.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Translational Research Institute for Metabolism and Diabetes</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patty Ford</last_name>
      <phone>407-303-7100</phone>
      <email>tri@flhosp.org</email>
    </contact>
    <investigator>
      <last_name>Steven R Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.trimd.org</url>
    <description>Florida Hospital Translational Research Institute for Metabolism and Diabetes</description>
  </link>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 12, 2017</lastchanged_date>
  <firstreceived_date>September 16, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adipose tissue</keyword>
  <keyword>calorimetry</keyword>
  <keyword>energy expenditure</keyword>
  <keyword>microbiome</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
